Clal Biotechnology (Israel) Financial Indicators Patterns

CBI -- Israel Stock  

ILS 314.20  4.10  1.32%

We suggest you to use Clal Biotechnology fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if Clal Biotechnology is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-one available fundamental indicators for Clal Biotechnology Industries Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Clal Biotechnology fundamentals including its Operating Margin, Revenue, Total Debt, as well as the relationship between Price to Earning and Net Income . Use Clal Biotechnology to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of Clal Biotechnology to be traded at S345.62 in 30 days

Clal Biotechnology Company Summary

Clal Biotechnology competes with Kamada Ltd, Compugen Ltd, Pluristem Therapeutics, Evogene Ltd, and Solegreen Ltd. Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. Clal Biotechnology operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.

Clal Biotechnology Debt to Equity vs Cash per Share

Clal Biotechnology Industries Ltd is rated second in debt to equity category among related companies. It is rated fourth in cash per share category among related companies fabricating about  0.07  of Cash per Share per Debt to Equity. The ratio of Debt to Equity to Cash per Share for Clal Biotechnology Industries Ltd is roughly  14.27 

Clal Biotechnology Market Fundamentals

 Change(%) 1.32%

Distress Rating

Clal Biotechnology Financial Distress Probability

Chance of Financial Distress
Clal Biotechnology Industries Ltd has less than 14 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Compare Clal Biotechnology

Compare Clal Biotechnology To Peers

Clal Biotechnology Opportunity Range

December 12, 2018 Opportunity Range

Check also Trending Equities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.